InnoCan Pharma's Wellness Engine Hits 2 Million Customers as Shareholders Prepare for a Defining Vote

InnoCan Pharma's August 17 vote on rebranding to Velsa Corp signals a shift to a wellness-funded pharma model, with Q1 revenue up 29.7% and a key FDA pathway for its lead drug.

The countdown to InnoCan Pharma's August 17 shareholder meeting is now measured in days, and the agenda carries more weight than a simple name change. When investors gather to vote on rebranding the company as Velsa Corp, they will effectively be endorsing a strategic identity that has been taking shape for months: a hybrid health-and-wellness group rather than a pure-play cannabinoid specialist.

The rebranding proposal — which will also see shareholders elect a new board and appoint auditors — is the formal acknowledgment of a business model the company calls "Wellness-to-Pharma." The phrase captures a strategy that sets InnoCan apart from most preclinical biotechs, which typically burn cash with no reliable revenue stream. Here, the consumer division is expected to fund the expensive human trials that lie ahead.

A Consumer Franchise With Momentum

The numbers behind that model are getting harder to ignore. In the first quarter of 2026, InnoCan generated revenue of $6.47 million, a 29.7 percent jump from the previous quarter. The growth engine is subsidiary B.I. Sky Global and its skincare brand Valitic, which crossed the 2 million customer threshold in late July.

That steady cash flow from consumer products is the financial backbone of the entire enterprise. The question investors are now wrestling with is whether it can stretch far enough to underwrite the costly clinical development program without forcing dilutive capital raises — and without further delays to the long-promised US listing.

The Pipeline: Progress and Patience

On the pharmaceutical side, the company's liposomal platform LPT-CBD has secured an INAD number from the US Food and Drug Administration, an early but meaningful step in the veterinary drug approval process. Peer-reviewed studies have shown the injectable technology outperforms placebo in managing chronic pain and mobility issues in pets, supporting a dual-track FDA strategy covering both animal and human medicine.

For the lead human drug candidate, regulators have signaled a shortened approval pathway, which could trim both development costs and time to market. That regulatory tailwind, combined with the margins from established wellness brands, gives InnoCan a cushion that many pre-revenue biotechs simply do not have.

Yet the biggest hurdle remains untouched: human clinical trials have not begun. The veterinary successes are intended as a blueprint for human applications, but the capital-intensive phase-one study is still on the horizon, and the company's ability to finance it without shareholder dilution is the central risk.

The Mechanics of the Vote

Shareholder participation in the upcoming vote comes with tight deadlines that only apply to a specific group of investors. Only those registered as of July 13, 2026, are eligible to cast a ballot, and proxy forms must be submitted by 10:00 AM Toronto time on August 13.

The ownership structure adds another layer of context. Private investors control roughly 82.99 percent of the shares, with Tamar Innovest holding 17.01 percent as the largest single shareholder. That concentration means the outcome is unlikely to be a cliffhanger, but the optics of a strong mandate matter for market sentiment.

A Stock That Moves — and a Listing That Waits

Trading on the Canadian Securities Exchange remains characteristically volatile, with weekly swings of up to 22 percent not uncommon. On German exchanges, the shares were changing hands at around €1.62 on August 4.

The long-discussed move to a major US exchange — Nasdaq or NYSE American — has been postponed multiple times. Without that listing, InnoCan lacks access to deeper liquidity and institutional capital, precisely the resources that multi-stage human trials demand. The rebranding to Velsa and continued growth in Valitic sales are widely seen as the two levers that could finally unlock a fresh attempt at a US listing.

What Comes Next

The immediate catalyst is the mood emerging from the mid-August shareholder meeting. A broad vote in favor of the rebranding, combined with sustained margins in the wellness division, would keep the focus firmly on clinical advancement of the LPT-CBD platform.

The quarterly results due at the end of August will provide the next test. Stable operational growth could generate the momentum needed for another push toward the US listing. A slowdown in consumer demand, by contrast, would likely sharpen the market's focus on the financing risks embedded in the pharma pipeline. The concrete milestones to watch: the official start of the phase-one human study — and an updated timeline for the stalled US listing.